• Publications
  • Influence
Efficacy and safety of a new immunoglobulin G product, Gammaplex®, in primary immunodeficiency diseases
This open‐label multi‐centre study evaluated a new intravenous immunoglobulin, Gammaplex®, in the treatment of 50 patients with primary immunodeficiency and significant hypogammglobulinaemia and found it to be effective and well tolerated.
Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075)
Gammaplex achieved a very high concentration of serum IgG but was well-tolerated and effective in the treatment of ITP with a similar degree of efficacy to the pre-determined historical control group and thePre-set statistical criteria.